Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults
NCT01260727
Completed
The purpose of this study is to evaluate the safety of and immune response to an HIV vaccine, administered using two different devices, followed by a vaccine boost, in healthy, HIV-uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
10/28/2021
Locations: Rockville Vaccine Assessment Clinic (RVAC), Rockville, Maryland +3 locations
Conditions: HIV Infections
Register for Updates
Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs
NCT00257127
Completed
The purpose of this study is to determine immune system function following vaccination in HIV-infected children currently taking anti-HIV drugs. To test the effectiveness of prior vaccination, patients in this study will receive booster shots of one of two pneumococcal vaccines, a hepatitis B vaccine, and a measles vaccine.
Gender:
ALL
Ages:
Between 6 years and 23 years
Trial Updated:
10/28/2021
Locations: UAB, Dept. of Ped., Div. of Infectious Diseases, Birmingham, Alabama +25 locations
Conditions: HIV Infections
Register for Updates
Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs
NCT00013871
Completed
The purpose of this study is to determine if 2 doses of Pneumococcal Conjugate Vaccine (PCV) followed by 1 dose of Pneumococcal Polysaccharide Vaccine (PPV) in HIV-infected children on anti-HIV therapy is helpful and safe in fighting pneumococcal infections in this group of children. This study will also look at the protection provided by childhood vaccination against measles, pertussis, and hepatitis B virus. Pneumococcal infections are the most common AIDS-related infection in HIV-infected ch... Read More
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
10/28/2021
Locations: UAB, Dept. of Ped., Div. of Infectious Diseases, Birmingham, Alabama +39 locations
Conditions: HIV Infections, Hepatitis B, Measles, Pneumococcal Infections, Pertussis
Register for Updates
Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents
NCT00091702
Completed
The purpose of this study is to compare two flu vaccines to determine their safety and ability to stimulate an immune response in HIV infected children and adolescents. This study will also determine how often and how long people who receive a vaccine are able to spread flu vaccine virus to other people.
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
10/28/2021
Locations: UAB, Dept. of Ped., Div. of Infectious Diseases, Birmingham, Alabama +60 locations
Conditions: HIV Infections, Influenza
Register for Updates
Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors
NCT02747407
Completed
This research trial studies qualitative, qualitative, and functional studies over the first year in measuring immune system response in patients with brain tumors. Measuring the number of immune cells, whether these immune cells work correctly, and response to 2 vaccines at several times during the first year of treatment may help find out how active the immune system responds to fight infection and cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2021
Locations: Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina
Conditions: Astrocytoma, Glioma, Oligodendroglioma
Register for Updates
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)
NCT00000767
Completed
To evaluate, in healthy HIV-1 seronegative vaccinia-immune and vaccinia-naive volunteers, the safety and immunogenicity of an HIV-1 candidate vaccine (TBC-3B) consisting of a live recombinant vaccinia virus expressing the env, gag, and pol genes of HIV-1 IIIB strain. To evaluate the potential of boosting with one of a variety of HIV-1 recombinant subunit, peptide, or pseudovirion vaccines, if available, to augment the immune responses of the vaccinees. Antigenic drift, defined as the genetic va... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
10/27/2021
Locations: St. Louis Univ. School of Medicine AVEG, Saint Louis, Missouri +4 locations
Conditions: HIV Infections
Register for Updates
A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen
NCT00000782
Completed
To determine the frequency of delayed-type hypersensitivity (DTH) reactions in HIV-positive patients to two doses of two envelope glycoprotein antigens prepared differently. To determine whether patients who have previously demonstrated a DTH response to intradermal MGStage HIV-1 gp160 IIIB baculovirus (MicroGeneSys) have a reproducible response to a repeat injection of gp160 and whether there is cross-reactivity to intradermal HIV-1 rgp160 IIIB vero cell expressed (Immuno-AG). PER 4/5/95 AMEND... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/27/2021
Locations: Stanford CRS, Palo Alto, California +3 locations
Conditions: HIV Infections
Register for Updates
A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants
NCT00000829
Completed
To assess whether HIV-infected infants who receive a heptavalent pneumococcal conjugate vaccine have more local reactions at the site of injection and systemic reactions than placebo subjects. To assess whether this vaccine is more immunogenic than placebo following the third vaccination. Children with HIV infection are at increased risk for invasive pneumococcal infection, particularly bacteremia. A large proportion of pneumococcal disease is caused by a limited number of serotypes. The maximu... Read More
Gender:
ALL
Ages:
Between 2 months and 6 months
Trial Updated:
10/27/2021
Locations: Usc La Nichd Crs, Los Angeles, California +32 locations
Conditions: HIV Infections, Pneumococcal Infections
Register for Updates
A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328
NCT00000943
Completed
The purpose of this study is to determine the effects of an HIV vaccine (Remune) on the immune system. This study involves patients who have received at least 60 weeks of anti-HIV therapy, either alone or in combination with IL-2, while enrolled in ACTG 328. Remune is an experimental HIV vaccine. To see how the body's immune system reacts, this vaccine will be given with 1 to 3 other vaccines, and skin tests will monitor the body's reaction.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/27/2021
Locations: Univ. of Iowa Healthcare, Div. of Infectious Diseases, Iowa City, Iowa +1 locations
Conditions: HIV Infections
Register for Updates
A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160
NCT00000745
Completed
To determine the reactivity and safety of HIV-1 recombinant envelope glycoprotein gp160. To determine the immunogenicity of gp160. Although recent advances have been made in antiviral therapy against AIDS, there is currently no cure. It is likely that ultimate control of the disease will depend on the development of safe and effective vaccines against HIV.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/27/2021
Locations: JHU AVEG, Pittsburgh, Pennsylvania +1 locations
Conditions: HIV Infections
Register for Updates
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals
NCT00000633
Completed
To determine the safety and immunogenicity of vaccinia-derived HIV-1 recombinant envelope glycoprotein (gp160) in asymptomatic HIV-infected adult volunteers. To compare safety and immunogenicity of two different schedules of gp160 administration. To examine the effects of gp160 and hepatitis B vaccine (Engerix-B) on various markers of viral load and on selected immune parameters. Potentiation of a patient's immune response to HIV might possibly prolong the period of clinical latency and protect... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
10/26/2021
Locations: Johns Hopkins Adult AIDS CRS, Baltimore, Maryland +1 locations
Conditions: HIV Infections
Register for Updates
Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals
NCT00272493
Completed
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a naturally occurring substance that is made by the body in response to infection or inflammation, and greatly improves cellular immune responses. The purpose of this study is to evaluate the safety and effectiveness of GM-CSF as an adjuvant to improve the immune response to hepatitis B virus (HBV) vaccination in HIV infected individuals.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2021
Locations: Northwestern University CRS, Chicago, Illinois +10 locations
Conditions: HIV Infections
Register for Updates